Show simple item record

dc.contributor.authorBot, M
dc.contributor.authorBrouwer, I
dc.contributor.authorRoca, M
dc.contributor.authorKohls, E
dc.contributor.authorPenninx, B
dc.contributor.authorWatkins, ER
dc.contributor.authorvan Grootheest, G
dc.contributor.authorCabout, M
dc.contributor.authorHegerl, U
dc.contributor.authorGili, M
dc.contributor.authorOwens, M
dc.contributor.authorVisser, M
dc.date.accessioned2019-02-14T11:51:04Z
dc.date.issued2019-03-05
dc.description.abstractImportance: Effects of nutritional interventions on the prevention of major depressive disorder (MDD) in overweight adults are unknown. Objective: To examine the effect of two nutritional strategies (multi-nutrient supplementation, food-related behavioral activation (F-BA) therapy) and their combination for prevention of a new MDD episode in overweight adults with subsyndromal depressive symptoms. Design, setting, participants: This multicenter 2x2 factorial randomized clinical trial included overweight adults (BMI 25-40kg/m2) aged 18-75years with elevated depressive symptoms (Patient Health Questionnaire-9 (PHQ-9) scores≥5) not meeting criteria for MDD episodes in the past 6 months from 4 European countries. 1025 adults were randomized between July-30-2015 and October-12-2016, and followed for 1 year (until October-13-2017). Interventions: Daily multi-nutrient supplements (1412mg omega-3 fatty acids, 30μg selenium, 400μg folic acid, and 20μg D-3 vitamin plus 100mg calcium) versus placebo (blinded), and/or 21 individual and group F-BA sessions versus no F-BA (blinded to researchers), for one year. Participants were allocated to placebo without F-BA (n=257), placebo with F-BA (n=256), supplements without F-BA (n=256), and supplements with F-BA (n=256). Main Outcomes and Measures: Primary outcome was cumulative 1-year onset of MDD measured with the Mini International Neuropsychiatric Interview after 3, 6 and 12 months. Logistic regression using effect-coded variables (-1 indicating control, +1 indicating intervention) evaluated intervention effects both individually and in combination (interaction) on MDD onset. Results: Among 1025 participants (mean age 46.5y; 772 (75%) women; mean BMI 31.4kg/m2), 779 (76%) completed the trial. During 12 month follow-up, 105 (10%) developed MDD (placebo without F-BA: 25 (9.7%), placebo with F-BA: 26 (10.2%), supplements without F-BA: 32 (12.5%), supplements with F-BA: 22 (8.6%).. Neither supplements (odds ratio (OR)=1.06; 95%-confidence interval (CI)=0.87-1.29), F-BA (OR=0.93; 95%CI=0.76-1.13), nor their combination (OR=0.93; 95%CI=0.76-1.14, p for interaction=0.48) affected MDD onset. Number of deaths/hospitalizations were for placebo without F-BA (n=0,n=24), placebo with F-BA (n=0,n=24), supplements without F-BA (n=0,n=26) and supplements with F-BA (n=1,n=24), respectively. Conclusions and Relevance: Among overweight or obese adults with depressive symptoms, multi-nutrient supplementation compared with placebo and food-related behavioral activation therapy compared with no therapy did not reduce episodes of major depressive disorder during 1 year. These findings do not support the use of these interventions for prevention of major depressive disorder. Trial registration: https://www.clinicaltrials.gov/ct2/show/NCT02529423. August-2015.en_GB
dc.description.sponsorshipEuropean Commissionen_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)
dc.identifier.citationVol. 321 (9), pp. 858-868.
dc.identifier.doi10.1001/jama.2019.0556
dc.identifier.grantnumber613598en_GB
dc.identifier.urihttp://hdl.handle.net/10871/35939
dc.language.isoenen_GB
dc.publisherAmerican Medical Association (AMA)en_GB
dc.rights.embargoreasonUnder embargo until 05 September 2019 in compliance with publisher policy.
dc.rights© 2019 American Medical Association. All rights reserved.
dc.titleEffect of Multinutrient Supplementation and Food-2 Related Behavioral Activation Therapy on 3 Prevention of Major Depressive Disorder Among 4 Overweight or Obese Adults With Subsyndromal 5 Depressive Symptomsen_GB
dc.typeArticleen_GB
dc.date.available2019-02-14T11:51:04Z
dc.identifier.issn0098-7484
dc.descriptionThis is the author accepted manuscript. The final version is available from the American Medical Association via the DOI in this record.en_GB
dc.identifier.journalJAMA - Journal of the American Medical Associationen_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2019-01-29
exeter.funder::European Commissionen_GB
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2019-01-29
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2019-02-14T09:58:20Z
refterms.versionFCDAM
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record